A study of idelalisib finds that this experimental targeted therapy drug may effectively treat chronic lymphocytic leukemia (CLL) patients without the need for chemotherapy. "The treatment today for CLL can be worse than the disease, leading to a great deal of side effects and death,” said lead investigator Richard R. Furman, MD, in a statement. “This study, and others we have conducted on idelalisib, demonstrates that we may no longer need to use chemotherapy in CLL." Read more here.
Study mentioned: Furman RR, et al. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2014 Jan 22. [Epub ahead of print] PMID: 24450857
No comments:
Post a Comment